Senior Medical DirectorTakeda PharmaceuticalsLexington, Massachusetts, United States
PB0225 - Evaluation of Real-world Treatment Patterns and Outcomes in Patients with Von Willebrand Disease Treated Prophylactically with recombinant Von Willebrand Factor in the United States: Interim Analysis
Sunday, June 25, 202318:30 – 19:30 ET
PB0324 - Burden of Symptoms and Healthcare Resource Utilization (HCRU) and Costs in U.S. Patients with Thrombotic Thrombocytopenic Purpura (TTP)
